{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:17:35Z","timestamp":1769015855104,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MSD China."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The world\u2019s first HIV integrase inhibitor, raltegravir (RAL), has been widely used for the treatment of HIV infection over the past 15 years, and continues benefiting people living with HIV (PLWH) today due to its efficient virological suppression and favourable safety profile. However, to date, there have not been any published systematic analyses evaluating the efficacy of RAL in HIV-positive pregnant women. Herein, our study aimed to evaluate the efficacy of raltegravir (RAL) regarding virological suppression at delivery in Human immunodeficiency virus (HIV)-positive pregnant women by systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we searched PubMed, EMBASE, the Cochrane Library, and Web of Science from inception until January 17th, 2023. Clinical trials and observational studies (cohort studies, case series, case reports) were included. All analyses were performed using R 4.1.1 statistical software with random effects modelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-two studies with 806 HIV-positive pregnant women were included. Pooled analysis indicated that the overall effectiveness rate for achieving virological suppression at delivery is 85% (95% confidence interval [CI]: 79% \u2212\u200990%). Analysis of secondary outcomes revealed an overall efficacy of 78% (95% CI: 72% \u2212\u200984%) for those with an HIV RNA load of &lt;\u20091000 RNA copies\/mL at delivery when RAL was initiated from the second trimester onward. Additionally, subgroup analysis showed an overall effectiveness rate of 75% (95% CI: 58% \u2212\u200987%) for treatment-na\u00efve (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929) and 76% (95% CI: 60%-86%) for treatment-experienced patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200938).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>It concluded that RAL is effective for achieving virological suppression at delivery in HIV-positive pregnant women, and possibly contribute to the prevention of mother-to-child HIV transmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This study was registered in PROSPERO, with registration number: CRD42023428508.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-025-08135-5","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T12:25:20Z","timestamp":1764159920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of raltegravir in achieving virological suppression at delivery in HIV-positive pregnant women: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengru","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanmei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"8135_CR1","unstructured":"World Health Organization (WHO). Key facts and lastest estimates on the global HIV epidemiac-2023. Available at www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids. Accessed on May 24, 2025."},{"issue":"1","key":"8135_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40249-022-00947-3","volume":"11","author":"D Shan","year":"2022","unstructured":"Shan D, Ning Z, Yu M, Zheng H, Yang J, Gong H, et al. HIV incidence and risk factors among transgender women and cisgender men who have sex with men in two cities of China: a prospective cohort study. Infect Dis Poverty. 2022;11(1):26. https:\/\/doi.org\/10.1186\/s40249-022-00947-3.","journal-title":"Infect Dis Poverty"},{"key":"8135_CR3","doi-asserted-by":"publisher","first-page":"652868","DOI":"10.3389\/fpubh.2021.652868","volume":"9","author":"Y Ma","year":"2021","unstructured":"Ma Y, Cui Y, Hu Q, Mubarik S, Yang D, Jiang Y, et al. Long-term changes of HIV\/AIDS incidence rate in China and the U.S. population from 1994 to 2019: a join-point and age-period-cohort analysis. Front Public Health. 2021;9:652868. https:\/\/doi.org\/10.3389\/fpubh.2021.652868.","journal-title":"Front Public Health"},{"issue":"3","key":"8135_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.idc.2014.06.001","volume":"28","author":"AK Pau","year":"2014","unstructured":"Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin North Am. 2014;28(3):371\u2013402. https:\/\/doi.org\/10.1016\/j.idc.2014.06.001.","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"8135_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/14740338.2018.1411903","volume":"17","author":"R de Miguel","year":"2018","unstructured":"de Miguel R, Montejano R, Stella-Ascariz N, Arribas JR. A safety evaluation of raltegravir for the treatment of HIV. Expert Opin Drug Saf. 2018;17(2):217\u201323. https:\/\/doi.org\/10.1080\/14740338.2018.1411903.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"8135_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1093\/cid\/civ366","volume":"61","author":"MI Blonk","year":"2015","unstructured":"Blonk MI, Colbers AP, Hidalgo-Tenorio C, Kabeya K, Weizsacker K, Haberl AE, et al. Raltegravir in HIV-1-infected pregnant women: pharmacokinetics, safety, and efficacy. Clin Infect Dis. 2015;61(5):809\u201316. https:\/\/doi.org\/10.1093\/cid\/civ366.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"8135_CR7","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/s2352-3018(20)30038-2","volume":"7","author":"EC Jo\u00e3o","year":"2020","unstructured":"Jo\u00e3o EC, Morrison RL, Shapiro DE, Chakhtoura N, Gouv\u00e8a MIS, de Lourdes BTM, et al. Raltegravir versus Efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial. Lancet HIV. 2020;7(5):e322\u201331. https:\/\/doi.org\/10.1016\/s2352-3018(20)30038-2.","journal-title":"Lancet HIV"},{"issue":"4","key":"8135_CR8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1086\/650005","volume":"50","author":"R Tubiana","year":"2010","unstructured":"Tubiana R, Le Chenadec J, Rouzioux C, Mandelbrot L, Hamrene K, Dollfus C, et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load\u2009<\u2009500 copies\/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis. 2010;50(4):585\u201396. https:\/\/doi.org\/10.1086\/650005.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"8135_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1155\/2015\/731043","volume":"26","author":"I Boucoiran","year":"2015","unstructured":"Boucoiran I, Tulloch K, Pick N, Kakkar F, van Schalkwyk J, Money D, et al. A case series of third-trimester raltegravir initiation: impact on maternal HIV-1 viral load and obstetrical outcomes. Can J Infect Dis Med Microbiol. 2015;26(3):145\u201350. https:\/\/doi.org\/10.1155\/2015\/731043.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"8135_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2011.01008.x","author":"M Rosenvinge","year":"2012","unstructured":"Rosenvinge M, Dosekun O, Rodgers M, Ramsay S, Perez K, Foster R, et al. A multicentre case series of raltegravir use in pregnancy. HIV Med. 2012. 1:1. https:\/\/doi.org\/10.1111\/j.1468-1293.2011.01008.x","journal-title":"HIV Med"},{"issue":"Suppl 1","key":"8135_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4067\/s0716-10182016000700007","volume":"33","author":"L Garc\u00eda-Fern\u00e1ndez","year":"2016","unstructured":"Garc\u00eda-Fern\u00e1ndez L, Fiestas F, V\u00e1squez R, Benites C. [Antiretroviral therapy containing raltegravir in HIV-infected pregnant women. Syst Review] Rev Chil Infectol. 2016;33(Suppl 1):60\u20136. https:\/\/doi.org\/10.4067\/s0716-10182016000700007.","journal-title":"Syst Review] Rev Chil Infectol"},{"issue":"2","key":"8135_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/qai.0000000000000932","volume":"72","author":"A Maliakkal","year":"2016","unstructured":"Maliakkal A, Walmsley S, Tseng A, Review C. Review of the efficacy, safety, and pharmacokinetics of raltegravir in pregnancy. J Acquir Immune Defic Syndr. 2016;72(2):153\u201361. https:\/\/doi.org\/10.1097\/qai.0000000000000932.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"8135_CR13","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"3","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3(3):e123\u201330. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00135.","journal-title":"Open Med"},{"issue":"5","key":"8135_CR14","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/qai.0000000000002287","volume":"83","author":"SA Lee","year":"2020","unstructured":"Lee SA, Telwatte S, Hatano H, Kashuba ADM, Cottrell ML, Hoh R, et al. Antiretroviral therapy concentrations differ in gut vs. lymph node tissues and are associated with HIV viral transcription by a novel RT-ddPCR assay. J Acquir Immune Defic Syndr. 2020;83(5):530\u20137. https:\/\/doi.org\/10.1097\/qai.0000000000002287.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"8135_CR15","unstructured":"Wells GSB, O\u2019Connell D, Peterson J, Welch V, Losos M et al. The New castle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.html. Accessed on June10 2023."},{"key":"8135_CR16","unstructured":"Higgins JPT G.S., Cochrane handbook for systematic reviews of interventions. Ver.5.1.0. Available at: https:\/\/ www.cochrane-handbook.org;cited. Accessed on June 10, 2023."},{"issue":"1","key":"8135_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1472-8206.2000.tb00391.x","volume":"14","author":"O Chung","year":"2000","unstructured":"Chung O, Hinder M, Sharma AM, B\u00f6nner G, Middeke M, Platon J, et al. Comparison of the efficacy and safety of Losartan (50\u2013100 mg) with the T-type calcium channel blocker mibefradil (50\u2013100 mg) in mild to moderate hypertension. Fundam Clin Pharmacol. 2000;14(1):31\u201341. https:\/\/doi.org\/10.1111\/j.1472-8206.2000.tb00391.x.","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"8135_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"key":"8135_CR19","volume-title":"Raltegravir plasma concentrations on HIV-1 infected pregnant women, in Conferance on retroviruses and oppuortunistic infections","author":"E Belissa","year":"2015","unstructured":"Belissa E, Benchikh A, Charpentier C, Valentin M, Bourgeois-Moine A, Lariven S, et al. Raltegravir plasma concentrations on HIV-1 infected pregnant women, in Conferance on retroviruses and oppuortunistic infections. Washington: Seattle; 2015."},{"issue":"3","key":"8135_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/15284336.2018.1459343","volume":"19","author":"C Brites","year":"2018","unstructured":"Brites C, N\u00f3brega I, Luz E, Travassos AG, Lorenzo C, Netto EM. Raltegravir versus lopinavir\/ritonavir for treatment of HIV-infected late-presenting pregnant women. HIV Clin Trials. 2018;19(3):94\u2013100. https:\/\/doi.org\/10.1080\/15284336.2018.1459343.","journal-title":"HIV Clin Trials"},{"issue":"2","key":"8135_CR21","doi-asserted-by":"publisher","DOI":"10.4081\/idr.2017.7017","volume":"9","author":"DM Cecchini","year":"2017","unstructured":"Cecchini DM, Martinez MG, Morganti LM, Rodriguez CG. Antiretroviral therapy containing raltegravir to prevent mother-to-child transmission of HIV in infected pregnant women. Infect Dis Rep. 2017;9(2):7017. https:\/\/doi.org\/10.4081\/idr.2017.7017.","journal-title":"Infect Dis Rep"},{"issue":"4","key":"8135_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216010","volume":"14","author":"P Gantner","year":"2019","unstructured":"Gantner P, Sylla B, Morand-Joubert L, Frange P, Lacombe K, Khuong MA, et al. Real life use of raltegravir during pregnancy in France: the Coferal-IMEA048 cohort study. PLoS One. 2019;14(4):e0216010. https:\/\/doi.org\/10.1371\/journal.pone.0216010.","journal-title":"PLoS One"},{"issue":"3","key":"8135_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1258\/ijsa.2012.012121","volume":"24","author":"A Hegazi","year":"2013","unstructured":"Hegazi A, Hay P. Hiv seroconversion in the third trimester of pregnancy: using raltegravir to prevent mother-to-child transmission. Int J STD AIDS. 2013;24(3):245\u20136. https:\/\/doi.org\/10.1258\/ijsa.2012.012121.","journal-title":"Int J STD AIDS"},{"issue":"18","key":"8135_CR24","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1097\/QAD.0b013e32835a9aeb","volume":"26","author":"A Hegazi","year":"2012","unstructured":"Hegazi A, Mc Keown D, Doerholt K, Donaghy S, Sadiq ST, Hay P. Raltegravir in the prevention of mother-to-child transmission of HIV-1: effective transplacental transfer and delayed plasma clearance observed in preterm neonates. AIDS. 2012;26(18):2421\u20133. https:\/\/doi.org\/10.1097\/QAD.0b013e32835a9aeb.","journal-title":"AIDS"},{"issue":"4","key":"8135_CR25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3851\/imp1558","volume":"15","author":"D Jaworsky","year":"2010","unstructured":"Jaworsky D, Thompson C, Yudin MH, Bitnun A, Brophy J, Samson L, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther. 2010;15(4):677\u201380. https:\/\/doi.org\/10.3851\/imp1558.","journal-title":"Antivir Ther"},{"issue":"15","key":"8135_CR26","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1097\/QAD.0b013e32833d8a50","volume":"24","author":"DA McKeown","year":"2010","unstructured":"McKeown DA, Rosenvinge M, Donaghy S, Sharland M, Holt DW, Cormack I, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS. 2010;24(15):2416\u20138. https:\/\/doi.org\/10.1097\/QAD.0b013e32833d8a50.","journal-title":"AIDS"},{"key":"8135_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.7448\/IAS.19.8.21487","volume":"19","author":"MS Medeiros","year":"2016","unstructured":"Medeiros MS, Moreira HP, Arruda EAG, Correa EA, De Sales YC, Teixeira GFD, et al. Raltegravir in HIV-1-infected pregnant women: MTCT prophylaxis and children safety case series. J Int AIDS Soc. 2016;19:24. https:\/\/doi.org\/10.7448\/IAS.19.8.21487.","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"8135_CR28","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1089\/aid.2013.0059","volume":"29","author":"I N\u00f3brega","year":"2013","unstructured":"N\u00f3brega I, Travassos AG, Haguihara T, Amorim F, Brites C. Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women. AIDS Res Hum Retroviruses. 2013;29(11):1451\u20134. https:\/\/doi.org\/10.1089\/aid.2013.0059.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"8135_CR29","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa2200600","volume":"387","author":"K Patel","year":"2022","unstructured":"Patel K, Huo Y, Jao J, Powis KM, Williams PL, Kacanek D, et al. Dolutegravir in pregnancy as compared with current HIV regimens in the United States. N Engl J Med. 2022;387(9):799\u2013809. https:\/\/doi.org\/10.1056\/NEJMoa2200600.","journal-title":"N Engl J Med"},{"issue":"9","key":"8135_CR30","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1093\/jac\/dkq264","volume":"65","author":"C Pinnetti","year":"2010","unstructured":"Pinnetti C, Baroncelli S, Villani P, Fantoni M, Tozzi V, De Luca A, et al. Rapid HIV-RNA decline following addition of raltegravir and Tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother. 2010;65(9):2050\u20132. https:\/\/doi.org\/10.1093\/jac\/dkq264.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"8135_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S2055-6640(20)30246-6","volume":"4","author":"T Puthanakit","year":"2018","unstructured":"Puthanakit T, Thepnarong N, Chaithongwongwatthana S, Anugulruengkitt S, Anunsittichai O, Theerawit T, et al. Intensification of antiretroviral treatment with raltegravir for pregnant women living with HIV at high risk of vertical transmission. J Virus Erad. 2018;4(2):61\u20135. https:\/\/doi.org\/10.1016\/S2055-6640(20)30246-6.","journal-title":"J Virus Erad"},{"key":"8135_CR32","unstructured":"Sibiude J, Dialla O, Tubiana R, Blanche S, Dollfus C, Frange P et al. Comparison of four classical PI- and raltegravir-based regimens during pregnancy, in Conference on Retroviruses and Opportunistic Infections. 2018: Boston, Massachusetts."},{"key":"8135_CR33","doi-asserted-by":"publisher","first-page":"A28","DOI":"10.1136\/sextrans-2015-052126.83","volume":"1","author":"JY Soh","year":"2015","unstructured":"Soh JY, Allan S. Progressive multifocal leukoencephalopathy in a HIV-positive pregnant woman-first case reported in the UK. Sex Transm Infect. 2015;1:A28. https:\/\/doi.org\/10.1136\/sextrans-2015-052126.83","journal-title":"Sex Transm Infect"},{"issue":"6","key":"8135_CR34","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1258\/ijsa.2011.010469","volume":"22","author":"N Taylor","year":"2011","unstructured":"Taylor N, Touzeau V, Geit M, Gisinger M, Egle A, Greil R, et al. Raltegravir in pregnancy: a case series presentation. Int J STD AIDS. 2011;22(6):358\u201360. https:\/\/doi.org\/10.1258\/ijsa.2011.010469.","journal-title":"Int J STD AIDS"},{"key":"8135_CR35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jogc.2019.09.022","volume":"42","author":"MJ Trahan","year":"2020","unstructured":"Trahan MJ, Boucher M, Renaud C, Karatzios C, Metras ME, Valois S, et al. Pregnancies among the first generation of survivors of perinatal HIV infection. J Obstet Gynaecol Can. 2020;42:446\u201352. https:\/\/doi.org\/10.1016\/j.jogc.2019.09.022.","journal-title":"J Obstet Gynaecol Can"},{"issue":"4","key":"8135_CR36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/qai.0000000000000318","volume":"67","author":"DH Watts","year":"2014","unstructured":"Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, et al. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014;67(4):375\u201381. https:\/\/doi.org\/10.1097\/qai.0000000000000318.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"8135_CR37","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1089\/apc.2012.0283","volume":"26","author":"K Westling","year":"2012","unstructured":"Westling K, Pettersson K, Kaldma A, Naver L. Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy. AIDS Patient Care STDs. 2012;26:714\u20137. https:\/\/doi.org\/10.1089\/apc.2012.0283.","journal-title":"AIDS Patient Care STDs"},{"issue":"3","key":"8135_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1179\/1973947812y.0000000066","volume":"25","author":"HL De Biagio","year":"2013","unstructured":"De Biagio HL, Bruzzone A, Sticchi B, Prinapori L, Gerbaldo R. Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review. J Chemother. 2013;25(3):181\u20133. https:\/\/doi.org\/10.1179\/1973947812y.0000000066.","journal-title":"J Chemother"},{"key":"8135_CR39","unstructured":"Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal. Accessed (2025.03.22)."},{"key":"8135_CR40","unstructured":"Leng T, Xu J, Kras A, Wood K, Doriswami R, Shadra C et al. AAO IRIS registry data replicates VIEW 1 and VIEW 2 clinical trial outcome data. Invest Ophthalmol Visual Sci, 2021;62(8):342."},{"key":"8135_CR41","doi-asserted-by":"publisher","unstructured":"Thea DM, Steketee RW, Pliner V, Bornschlegel K, Brown T, Orloff S, et al. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. AIDS. 1997;11(4):437\u201344. https:\/\/doi.org\/10.1097\/00002030-199704000-00006.","DOI":"10.1097\/00002030-199704000-00006"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-025-08135-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-025-08135-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-025-08135-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:05:05Z","timestamp":1768914305000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12884-025-08135-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8135"],"URL":"https:\/\/doi.org\/10.1186\/s12884-025-08135-5","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"27 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All analyses were based on previously published studies; therefore, no ethics approval or patient consent was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree with the publication of this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jie Liu and Huanmei Wu are employees of MSD China. All authors declared that there were no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}